Cytodyn Inc (CYDY)

[BlackDoggie]

Define expensive. Then review the cash recently raised, plus the ~$30mm (current terms are for an average revenue to the firm of $0.30/share after warrants and broker fees) the company has left as headroom from A/S. Then consider how much cash is needed to finish the combo BLA, the 510k for the diagnostic, and maybe the initial TNBC trial. Ignore costs related to the mono, GvHD, and colon cancer trials, as they should be postponed in this scenario. I'm working on the (potentially unrealistic) assumption that strong cancer data would not spark an acceptable partnership.

How much cash would that then leave the company to hire away a few experienced members of Gilead's sales team, for example?

I believe you're overstating the cost and difficulty versus the company's capability, were they to slow clinical progress down to near-revenue activities only. Overstating the risk? Maybe not. But if the reward is not handing ~50% or more of gross revenues to BP just because they're kind enough to agree to sell a product that they've shouldered no risk in developing, I personally will take that risk all day long.

We may have to agree to disagree on this one, and that's fine.